PLoS ONE (Jan 2020)

Plasma proteomic profiling suggests an association between antigen driven clonal B cell expansion and ME/CFS.

  • Milica Milivojevic,
  • Xiaoyu Che,
  • Lucinda Bateman,
  • Aaron Cheng,
  • Benjamin A Garcia,
  • Mady Hornig,
  • Manuel Huber,
  • Nancy G Klimas,
  • Bohyun Lee,
  • Hyoungjoo Lee,
  • Susan Levine,
  • Jose G Montoya,
  • Daniel L Peterson,
  • Anthony L Komaroff,
  • W Ian Lipkin

DOI
https://doi.org/10.1371/journal.pone.0236148
Journal volume & issue
Vol. 15, no. 7
p. e0236148

Abstract

Read online

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is an unexplained chronic, debilitating illness characterized by fatigue, sleep disturbances, cognitive dysfunction, orthostatic intolerance and gastrointestinal problems. Using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), we analyzed the plasma proteomes of 39 ME/CFS patients and 41 healthy controls. Logistic regression models, with both linear and quadratic terms of the protein levels as independent variables, revealed a significant association between ME/CFS and the immunoglobulin heavy variable (IGHV) region 3-23/30. Stratifying the ME/CFS group based on self-reported irritable bowel syndrome (sr-IBS) status revealed a significant quadratic effect of immunoglobulin lambda constant region 7 on its association with ME/CFS with sr-IBS whilst IGHV3-23/30 and immunoglobulin kappa variable region 3-11 were significantly associated with ME/CFS without sr-IBS. In addition, we were able to predict ME/CFS status with a high degree of accuracy (AUC = 0.774-0.838) using a panel of proteins selected by 3 different machine learning algorithms: Lasso, Random Forests, and XGBoost. These algorithms also identified proteomic profiles that predicted the status of ME/CFS patients with sr-IBS (AUC = 0.806-0.846) and ME/CFS without sr-IBS (AUC = 0.754-0.780). Our findings are consistent with a significant association of ME/CFS with immune dysregulation and highlight the potential use of the plasma proteome as a source of biomarkers for disease.